The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -17,695 |
| Loss on impairment of intangible assets | 6,995 |
| Loss on debt extinguishment | -3,260 |
| Depreciation and amortization | 2,115 |
| Stock-based compensation | 338 |
| Change in fair value of royalties payable due to related parties | 5,709 |
| Change in fair value of convertible notes payable | 2 |
| Net loss on trading debt securities | -564 |
| Deferred income tax provision (benefit) | -1,810 |
| Acquired in-process research and development | 1,967 |
| Amortization of discount on note payable | 45 |
| Accounts receivable | 85 |
| Inventories | 78 |
| Prepaid expenses and other current assets | -255 |
| Operating lease right-of-use assets and lease liabilities | -4 |
| Current portion of royalties payable due to related parties | 19 |
| Accounts payable | 1,156 |
| Accrued expenses | 149 |
| Interest payable-Related Party | 185 |
| Interest payable-Variable Interest Entity Not Primary Beneficiary | 39 |
| Net cash used in operating activities | -8,296 |
| Consideration paid for the acquired in-process research and development | 116 |
| Purchases of property and equipment | 17 |
| Proceeds from the sale of trading debt securities | 300 |
| Net cash provided by (used in) investing activities | 167 |
| Proceeds from issuance of series b convertible preferred stock and other equity-classified warrants, net of issuance costs-Series BConvertible Preferred Stock | 1,170 |
| Proceeds from issuance of common stock-September2024Public Offering | 0 |
| Proceeds from issuance of common stock-The2024Inducement Offer | 0 |
| Proceeds from issuance of common stock-Atm Offering | 3,751 |
| Proceeds from notes payable due to related parties | 300 |
| Proceeds from issuance of convertible notes payable | 300 |
| Payments on short-term notes payable | 238 |
| Proceeds from short-term notes payable | 61 |
| Proceeds from exercise of warrants | 0 |
| Net cash provided by financing activities | 5,344 |
| Net change in cash and cash equivalents | -2,785 |
| Cash and cash equivalents, beginning of year | 2,873 |
| Cash and cash equivalents, end of year | 88 |
Catheter Precision, Inc. (VTAK)
Catheter Precision, Inc. (VTAK)